Jesse Nevarez is a partner in the New York office and is a member of the Emerging Companies + Venture Capital practice group.

Jesse advises startups, growth-stage, and later-stage companies primarily in the technology, healthcare, and life sciences industries, including those in the artificial intelligence, fintech, ad-tech, clean energy, digital media, software, consumer, digital health, biotechnology, pharmaceuticals, medical devices and diagnostics spaces, and related fields. As part of his practice, he counsels companies on a range of matters, such as entity formation, seed and venture capital financings, growth equity investments, mergers and acquisitions, SEC compliance, IPOs, and other capital markets transactions. Additionally, he regularly represents venture capital firms and investment banks on a variety of investor-side deals.

Jesse has been named to the Lawyers of Color “Hot List” and named a Massachusetts Super Lawyer “Rising Star.”

He has previously served as a member of the Massachusetts Black Lawyers Association and the Boston College Law School Black Alumni Network, while also serving as a mentor for the MIT $100K Launch Competition.

Selected Venture Financings

• Scope3, PBC in its Series A and Series B financings
• Firsthand Labs, Inc. in its Series Seed financing
• Cockroach Labs, Inc. in its Series F financing and secondary transactions
• Freshly Inc. in its Series B, Series C, and Series C-1 financings
• CMDTY Inc. in its Series A financing
• Podium Data, Inc. in its Series Seed and Series A financings
• Yumanity Therapeutics in its Series A, Series B, and Series C financings
• Enspire DBS Therapy in its Series A financing

Selected Mergers + Acquisitions

• Open Lending, LLC in its business combination with Nebula Acquisition Corporation, a publicly traded special purpose acquisition company
• TripAdvisor in its acquisition of Viator
• TAG Manufacturing in its acquisition by Center Rock Capital Partners
• Neon Therapeutics, Inc. in its acquisition by BioNTech
• Lysosomal Therapeutics, Inc. in its exclusive option agreement with Allergan plc

Selected Public Offerings

• Sage Therapeutics, Inc. in its $103.5 million initial public offering and several follow-on public offerings raising an aggregate of $2.07 billion
• Neon Therapeutics, Inc. in its $100 million initial public offering
• Magenta Therapeutics, Inc. in its $100 million initial public offering
• Ascentage Pharma Group International in its $61 million initial public offering
• TPI Composites, Inc. in its $79 million initial public offering
• Plug Power Inc. in follow-on offerings raising an aggregate of $146.8 million